Zein: Potential biopolymer in inflammatory bowel diseases

IF 3.9 3区医学 Q2 ENGINEERING, BIOMEDICAL Journal of biomedical materials research. Part A Pub Date : 2024-08-29 DOI:10.1002/jbm.a.37785

Nimeet Desai, Smit Nayi, Dignesh Khunt, Devesh U. Kapoor, Sagar Salave, Bhupendra Prajapati, Chintan Vora, Rishabha Malviya, Rahul Maheshwari, Ravi Patel

{"title":"Zein: Potential biopolymer in inflammatory bowel diseases","authors":"Nimeet Desai, Smit Nayi, Dignesh Khunt, Devesh U. Kapoor, Sagar Salave, Bhupendra Prajapati, Chintan Vora, Rishabha Malviya, Rahul Maheshwari, Ravi Patel","doi":"10.1002/jbm.a.37785","DOIUrl":null,"url":null,"abstract":"<p>Effectively managing inflammatory bowel disease (IBD) poses difficulties due to its persistent nature and unpredictable episodes of exacerbation. There is encouraging evidence that personalized medication delivery systems can improve therapy efficacy while reducing the negative effects of standard medicines. Zein, a protein produced from corn, has garnered interest as a possible means of delivering drugs for the treatment of IBD. This review delves into Zein-based drug delivery systems, showcasing its biodegradability, controlled release capabilities, and biocompatibility. Studies have shown that Zein-based nanoparticles, microcarriers, and core-shell microparticles have the capacity to increase medication stability, enhance targeting in the intestines, and decrease toxicity in animal models of IBD. The review highlights the promise of Zein in personalized therapy for IBD and urges more study to enhance its clinical use.</p>","PeriodicalId":15142,"journal":{"name":"Journal of biomedical materials research. Part A","volume":"113 1","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biomedical materials research. Part A","FirstCategoryId":"5","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jbm.a.37785","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Effectively managing inflammatory bowel disease (IBD) poses difficulties due to its persistent nature and unpredictable episodes of exacerbation. There is encouraging evidence that personalized medication delivery systems can improve therapy efficacy while reducing the negative effects of standard medicines. Zein, a protein produced from corn, has garnered interest as a possible means of delivering drugs for the treatment of IBD. This review delves into Zein-based drug delivery systems, showcasing its biodegradability, controlled release capabilities, and biocompatibility. Studies have shown that Zein-based nanoparticles, microcarriers, and core-shell microparticles have the capacity to increase medication stability, enhance targeting in the intestines, and decrease toxicity in animal models of IBD. The review highlights the promise of Zein in personalized therapy for IBD and urges more study to enhance its clinical use.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Zein：炎症性肠病的潜在生物聚合物。

由于炎症性肠病（IBD）具有顽固性和难以预测的病情恶化，因此有效控制该病十分困难。有令人鼓舞的证据表明，个性化给药系统可以提高疗效，同时减少标准药物的负面影响。玉米蛋白 Zein 作为一种治疗 IBD 的可能给药方式，引起了人们的兴趣。本综述深入探讨了基于 Zein 的给药系统，展示了它的生物降解性、控释能力和生物相容性。研究表明，基于 Zein 的纳米颗粒、微载体和核壳微颗粒有能力提高药物的稳定性，增强在肠道中的靶向性，并降低 IBD 动物模型的毒性。这篇综述强调了 Zein 在 IBD 个性化治疗中的前景，并呼吁开展更多研究以提高其临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of biomedical materials research. Part A 工程技术-材料科学：生物材料

CiteScore

10.40

自引率

2.00%

发文量

135

审稿时长

3.6 months

期刊介绍： The Journal of Biomedical Materials Research Part A is an international, interdisciplinary, English-language publication of original contributions concerning studies of the preparation, performance, and evaluation of biomaterials; the chemical, physical, toxicological, and mechanical behavior of materials in physiological environments; and the response of blood and tissues to biomaterials. The Journal publishes peer-reviewed articles on all relevant biomaterial topics including the science and technology of alloys,polymers, ceramics, and reprocessed animal and human tissues in surgery,dentistry, artificial organs, and other medical devices. The Journal also publishes articles in interdisciplinary areas such as tissue engineering and controlled release technology where biomaterials play a significant role in the performance of the medical device. The Journal of Biomedical Materials Research is the official journal of the Society for Biomaterials (USA), the Japanese Society for Biomaterials, the Australasian Society for Biomaterials, and the Korean Society for Biomaterials. Articles are welcomed from all scientists. Membership in the Society for Biomaterials is not a prerequisite for submission.